<!– –> Long Term Lifecycle Planning for CGT Networks and Manufacturing Platforms Cell and Gene Therapy (CGT) products are at the forefront of advanced therapeutics, offering transformative potential for treating previously intractable diseases. However, the regulatory landscape governing CGT presents unique challenges, particularly when it comes to lifecycle planning, comparability, and management of process changes. This article serves as a comprehensive regulatory tutorial for Regulatory, CMC, clinical, and QA leaders working on cell and gene therapy products. In this article, we will explore effective strategies for long-term lifecycle planning within CGT networks and manufacturing platforms, focusing on key areas such…

Inspection Readiness for Comparability Evidence in CGT Facilities In the rapidly evolving landscape of cell and gene therapy (CGT) product development, ensuring compliance with regulatory frameworks is paramount. A well-structured approach to the CGT comparability process, especially in light of process changes and scale-up, is essential for successful product approval and market readiness. This article serves as a comprehensive guide aimed at Regulatory, Chemistry Manufacturing and Controls (CMC), clinical, and Quality Assurance (QA) leaders, traversing the necessary steps required to attain inspection readiness concerning comparability evidence in CGT facilities. Understanding Comparability in CGT Comparability is the cornerstone of assuring that…

Digital Twins and Modelling Concepts Applied to CGT Process Changes Understanding the Regulatory Landscape of Cell and Gene Therapy Cell and Gene Therapy (CGT) represents a rapidly evolving field within the biopharmaceutical industry, focusing on innovative treatment strategies for previously hard-to-manage diseases. The regulatory framework governing CGT in the United States, Europe, and the United Kingdom is complex yet essential for ensuring patient safety and therapy efficacy. Navigating this landscape necessitates a thorough understanding of relevant regulations such as 21 CFR Parts 210 and 211, which dictate current Good Manufacturing Practices (cGMP) for the production of pharmaceuticals and biologics, along…

Tech Transfer Strategies for CGT Across Internal and CDMO Sites Introduction to Tech Transfer in Cell and Gene Therapy As the field of cell and gene therapy (CGT) continues to evolve, the importance of effective tech transfer processes has become increasingly evident. Tech transfer encompasses the various activities involved in transferring a manufacturing process from one site to another, whether that be from an internal facility to a Contract Development and Manufacturing Organization (CDMO) or between facilities within a company. The regulatory landscape for CGT is particularly stringent, given the complex nature of these products and the need for rigorous…

Governance for Recurring Comparability Reviews Across the CGT Lifecycle Cell and gene therapy (CGT) products are at the forefront of innovative medical treatments, yet the regulatory landscape for these therapies poses significant challenges in terms of comparability during various phases of development, including post-approval changes, process evolution, and scale-up activities. This article provides a comprehensive step-by-step tutorial for regulatory, CMC, clinical, and QA leaders, focusing on the governance structure and processes necessary to manage and document comparability effectively throughout the CGT lifecycle. We will explore key aspects of analytical comparability and the implications of tech transfer in CGT, all within…